Mineralys Therapeutics (Nasdaq: MLYS) priced an underwritten public offering of 5,660,378 shares of common stock at $26.50 per share, for expected gross proceeds of about $150 million before expenses.
Net proceeds will help fund a $200 million upfront payment to repurchase a royalty obligation under a Tanabe Pharma license. The offering should close on or about June 4, 2026, subject to customary conditions. Earlier the company entered into a $500 million committed debt facility with funds managed by Pharmakon Advisors.
Loading...
Loading translation...
Positive
Common stock offering expected to raise about $150 million gross proceeds
Shares priced at $26.50, providing defined equity capital terms
Net proceeds earmarked to help fund $200 million royalty repurchase payment
$500 million committed debt facility expands available financing capacity
Negative
Issuance of 5,660,378 new shares implies equity dilution for existing holders
Offering proceeds subject to underwriting discounts, commissions and expenses reducing net cash
Transaction closing remains subject to customary closing conditions, adding some execution risk
News Market Reaction – MLYS
-13.14%3.5x vol
35 alerts
-13.14%Session close to close
-14.0%Trough in 5 hr 18 min
$2.38BMarket Cap
3.5xRel. Volume
In the Jun 3 session, MLYS declined 13.14%, reflecting a significant negative market reaction.
Argus tracked a trough of -14.0% from its starting point during tracking.
Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility.
Trading volume was very high at 3.5x the daily average, suggesting heavy selling pressure.
The stock dropped -13.1% in the session following this news. A negative reaction despite the stated ...
Analysis
The stock dropped -13.1% in the session following this news. A negative reaction despite the stated strategic use of proceeds fits a common pattern where equity offerings are viewed through a dilutive lens. MLYS traded at 28.85, down 7.26%, with the stock already 39.45% below its 52-week high and below its 200-day MA. Historically, most Mineralys offerings saw milder moves, so a sharper pullback could reflect supply overhang or broader biotech pressure rather than a change in the underlying NDA or lorundrostat trajectory.
Key Figures
Offering size:$150.0 millionShares offered:5,660,378 sharesOffering price:$26.50 per share+2 more
5 metrics
Offering size$150.0 millionGross proceeds from underwritten common stock offering
Shares offered5,660,378 sharesCommon stock in current underwritten offering
Offering price$26.50 per sharePrice for current common stock offering
Upfront payment$200.0 millionPortion of royalty repurchase upfront payment to Tanabe Pharma
Debt facility$500 millionCommitted debt facility with funds managed by Pharmakon Advisors
Priced $175.0M offering of 12,962,962 shares at $13.50.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Offering-related announcements have historically seen mostly positive or mixed one-day reactions, with only one clearly negative move in the provided set.
Recent Company History
Recent history for Mineralys shows repeated equity raises to fund development of lorundrostat. Since March–September 2025, the company completed or priced several offerings, with gross proceeds noted at $175.0M, $201.2M, $250.0M, and $287.5M. Most prior offering headlines were followed by modestly positive one-day moves, though one March 2025 pricing event saw an 8.32% decline. Today’s offering continues this capital-raising pattern as the program advances.
"announced today the pricing of an underwritten offering of 5,660,378 shares"
An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.
royalty obligationfinancial
"fund a portion of the $200.0 million upfront payment for the repurchase of the royalty obligation"
A royalty obligation is a legal promise to pay a continuing fee—often a percentage of sales or a fixed amount—for the right to use someone else’s asset, such as a patent, trademark, mineral rights, or technology. Think of it like paying rent for a tool or recipe: it reduces the owner’s available profits and creates an ongoing cash outflow that can affect a company’s earnings, valuation, and risk profile, so investors watch them to gauge future cash flow and profitability.
license agreementregulatory
"royalty obligation under its license agreement with Tanabe Pharma Corporation"
A license agreement is a contract where the owner of intellectual property, technology, a brand, or other rights gives another party permission to use those assets under specified conditions, usually for fees, royalties or other payments. For investors it matters because such deals create or limit predictable revenue streams, affect profit margins, transfer legal and commercial risk, and can determine how quickly a company can grow — like renting out a patented tool to earn steady income while keeping ownership.
committed debt facilityfinancial
"entering into a $500 million committed debt facility with funds managed by Pharmakon Advisors"
A committed debt facility is a loan or credit line that a lender has legally agreed to provide up to a set amount for a specified period, giving a borrower a guaranteed source of funds when needed. Think of it as a bank-backed safety net you can draw on for operations, expansion, or paying other obligations. For investors, the presence and size of such a facility signal reliable short-term funding, lower cash‑flow risk, and greater financial flexibility—factors that influence creditworthiness and the company’s ability to execute plans.
shelf registration statementregulatory
"offered by Mineralys pursuant to a shelf registration statement that became automatically effective"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplementregulatory
"A prospectus supplement and accompanying prospectus relating to this offering will be filed"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
book-running managersfinancial
"BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers"
Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten offering of 5,660,378 shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $150.0 million. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about June 4, 2026, subject to the satisfaction of customary closing conditions.
BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the offering.
Mineralys intends to use the net proceeds from the offering to fund a portion of the $200.0 million upfront payment for the repurchase of the royalty obligation under its license agreement with Tanabe Pharma Corporation. Earlier today, Mineralys announced entering into a $500 million committed debt facility with funds managed by Pharmakon Advisors, LP.
The securities described above are being offered by Mineralys pursuant to a shelf registration statement that became automatically effective upon filing with the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: BofA Securities NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, via fax: 212-902-9316, or via email: prospectus-ny@ny.email.gs.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific.
Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the completion of the proposed offering and the anticipated use of proceeds therefrom. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Mineralys’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the proposed offering, and the other risks described in Mineralys’ filings with the SEC, including under the heading “Risk Factors” in Mineralys’ most recent Annual Report on Form 10-K and any subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Media Relations Melyssa Weible Elixir Health Public Relations Email: mweible@elixirhealthpr.com
FAQ
What did Mineralys Therapeutics (MLYS) announce about its June 2026 stock offering?
Mineralys Therapeutics announced an underwritten public offering of 5,660,378 common shares at $26.50 per share. According to the company, the deal is expected to generate approximately $150 million in gross proceeds, before underwriting discounts, commissions and other offering expenses.
How much money will Mineralys Therapeutics (MLYS) raise in its June 2026 offering?
Mineralys Therapeutics expects to raise about $150 million in gross proceeds from the offering. According to the company, this is based on selling 5,660,378 common shares at $26.50 each, before deducting underwriting discounts, commissions and other estimated offering expenses.
What is the purpose of the Mineralys Therapeutics (MLYS) $150 million stock offering?
Mineralys Therapeutics plans to use net proceeds to fund part of a $200 million upfront payment. According to the company, this payment relates to the repurchase of a royalty obligation under its license agreement with Tanabe Pharma Corporation.
When is the Mineralys Therapeutics (MLYS) offering expected to close?
The Mineralys Therapeutics offering is expected to close on or about June 4, 2026. According to the company, closing is subject to the satisfaction of customary closing conditions typical for underwritten equity offerings.
How many new shares is Mineralys Therapeutics (MLYS) issuing and at what price?
Mineralys Therapeutics is issuing 5,660,378 shares of common stock at $26.50 per share. According to the company, all securities in the offering are being sold by Mineralys, resulting in new equity issuance to investors.
What other financing did Mineralys Therapeutics (MLYS) announce alongside the stock offering?
Alongside the stock offering, Mineralys Therapeutics entered into a $500 million committed debt facility with funds managed by Pharmakon Advisors. According to the company, this facility provides additional access to debt capital beyond the equity proceeds.
How is Mineralys Therapeutics (MLYS) conducting the June 2026 equity offering?
Mineralys Therapeutics is conducting the offering under an automatically effective shelf registration statement filed with the SEC. According to the company, a prospectus supplement and accompanying prospectus will be filed and made available through the SEC and the joint book-running managers.
